Literature DB >> 20382189

Ghrelin: a potential therapeutic target for cancer.

Dimitrios Nikolopoulos1, Stamatis Theocharis, Gregory Kouraklis.   

Abstract

Ghrelin is a recently identified 28-amino-acid peptide, capable of stimulating pituitary growth hormone release in humans and other mammals. It is mainly secreted from the gastric mucosa, but it is also widely expressed in a variety of tissues, in both normal and malignant conditions. Ghrelin has a multiplicity of physiological functions in gastrointestinal, cardiovascular, pulmonary and immune system, and also exerts a variety of roles, from increasing food intake (orexigenic effect) to affecting cell proliferation. The actions of ghrelin are mediated by the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R). The purpose of this review is to provide an overview of the expression and putative role of ghrelin and its receptor in cancer. Ghrelin and its receptor are detected in tumor tissues, and evidence is emerging that ghrelin plays an autocrine/paracrine role in cancer and could serve as a diagnostic or prognostic tool or as therapeutic target. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20382189     DOI: 10.1016/j.regpep.2010.03.011

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  23 in total

1.  Ghrelin- and serotonin-producing gastric carcinoid.

Authors:  Eleanor Latta; Fabio Rotondo; Lawrence A Leiter; Eva Horvath; Kalman Kovacs
Journal:  J Gastrointest Cancer       Date:  2012-06

2.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

3.  Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer.

Authors:  Xiaoyou Li; Xia Zhao; Chenchen Li; Siwen Liu; Fei Yan; Yue Teng; Jifeng Feng; Dengshun Miao
Journal:  Hum Cell       Date:  2019-04-24       Impact factor: 4.174

Review 4.  Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?

Authors:  Mark D DeBoer
Journal:  Mol Cell Endocrinol       Date:  2011-02-25       Impact factor: 4.102

5.  Ghrelin augments murine T-cell proliferation by activation of the phosphatidylinositol-3-kinase, extracellular signal-regulated kinase and protein kinase C signaling pathways.

Authors:  Jun Ho Lee; Kalpesh Patel; Hyun Jin Tae; Ana Lustig; Jie Wan Kim; Mark P Mattson; Dennis D Taub
Journal:  FEBS Lett       Date:  2014-11-18       Impact factor: 4.124

Review 6.  The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: efficacy and mechanism.

Authors:  Mark D DeBoer
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  The relationship between serum ghrelin and the risk of gastric and esophagogastric junctional adenocarcinomas.

Authors:  Gwen Murphy; Farin Kamangar; Sanford M Dawsey; Frank Z Stanczyk; Stephanie J Weinstein; Philip R Taylor; Jarmo Virtamo; Christian C Abnet; Demetrius Albanes; Neal D Freedman
Journal:  J Natl Cancer Inst       Date:  2011-06-21       Impact factor: 13.506

8.  What can anorexia nervosa teach us about appetite regulation?

Authors:  Mark D DeBoer
Journal:  Nutrition       Date:  2011-04       Impact factor: 4.008

9.  Ghrelin promotes oral tumor cell proliferation by modifying GLUT1 expression.

Authors:  Dominik Kraus; Jan Reckenbeil; Matthias Wenghoefer; Helmut Stark; Matthias Frentzen; Jean-Pierre Allam; Natalija Novak; Stilla Frede; Werner Götz; Rainer Probstmeier; Rainer Meyer; Jochen Winter
Journal:  Cell Mol Life Sci       Date:  2015-09-25       Impact factor: 9.261

10.  Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model.

Authors:  R Northrup; K Kuroda; E Manning Duus; S Routt Barnes; L Cheatham; T Wiley; C Pietra
Journal:  Support Care Cancer       Date:  2013-04-12       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.